Search
for
Sort by
Research 241–270 of 531
- 1315 An Integrated model of alopecia areata biomarkers highlights both Th1/Th2 upregulation, with stronger correlations between Th2 activation and disease severity
- 1312 Nrf2 activation enhances the healing of cutaneous wounds through the activation of hair follicle stem cells
- 1311 Efficacy of topical tofacitinib in promoting hair growth in non-scarring alopecia
- Medications
- British Society for Dermatopathology
- Review article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel disease
- Dermatolojik Problemler ve COVID-19
- ORAL TOFACITINIB IN MODERATE AND SEVERE ALOPECIA AREATA: CASE SERIES OF 14 PATIENTS
- Systematic review and indirect treatment comparisons of ritlecitinib against baricitinib in alopecia areata
- Maintenance, withdrawal, and re-treatment with ritlecitinib and brepocitinib in patients with alopecia areata in a single-blind extension of a phase 2a randomized clinical trial
- 67 Patterns of clinical response in patients with alopecia areata (AA) treated with ritlecitinib in the ALLEGRO phase 2b/3 and ongoing, phase 3, ALLEGRO-LT studies
- 186 Mechanistic insights into Ritlecitinib-mediated immunomodulation in Alopecia Areata
- Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers
- Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A promising therapy for the treatment of alopecia areata: A case report of six patients
- Clinical response to oral tofacitinib in pediatric patients with alopecia areata
- A Cost-per-Responder Analysis of Ritlecitinib vs Baricitinib in Severe Alopecia Areata
- Therapeutic update on alopecia areata: a critical review of standard and emerging targeted therapies
- Systemic Treatment of Moderate to Severe Alopecia Areata in Adults: Updated Australian Expert Consensus Statement
- A Patient Preference-Weighted Quantitative Benefit-Risk Analysis of Ritlecitinib for Alopecia Areata to Inform Medical Decision Making
- Using patient preference to inform ritlecitinib dose selection for alopecia areata treatment
- LB1034 Meta-analysis of scalp transcriptome defines alopecia areata subtypes and molecular response to four (4) treatments with jak inhibiting properties
- P88 Real-world evidence on efficacy and safety of Janus Kinase inhibitors in the treatment of moderate to severe active Ulcerative Colitis
- Current best evidence in pigmentary dermatology
- 705 Particulate matter induces inflammatory response in human outer root sheath cells via oxidative stress-dependent MAPK and JAK-STAT signaling pathways
- Interleukin-15 and Tumor Necrosis Factor-α in Iraqi Patients with Alopecia Areata
- Case Report: Successful Treatment of Alopecia Universalis With Tofacitinib and Increased Cytokine Levels: Normal Therapeutic Reaction or Danger Signal?
- Pharmacologic inhibition of JAK-STAT signaling promotes hair growth
- Targeting the Janus Kinase Family in Autoimmune Skin Diseases
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)
- New and Emerging Therapies for Alopecia Areata